Breast Cancer Treatment: Evidence-Based Recommendations

Core Treatment Principle

Treatment must be delivered by a specialized multidisciplinary breast team and should be based on tumor biology (hormone receptor status, HER2 status, grade), tumor burden (size, nodal involvement), and patient factors (age, menopausal status, preferences)—not on any single factor alone. 1

Multidisciplinary Team Requirements

The following specialists are mandatory for optimal breast cancer care:

Medical oncologist 1
Breast surgeon 1
Radiation oncologist 1
Breast radiologist 1
Breast pathologist 1
Breast nurse or specialized navigator 1

Access to plastic/reconstructive surgeons, psychologists, physiotherapists, and geneticists must be available when appropriate 1.

Surgical Management Algorithm

Breast-Conserving Surgery (BCS)

BCS with radiation is the preferred surgical approach for the majority of early breast cancer patients, as it provides equivalent survival to mastectomy with superior quality of life. 1, 2

Key requirements for BCS:

No tumor at the inked margin is required 1
Greater than 2 mm margin for in situ disease is preferred 1
Oncoplastic techniques should be used when needed to maintain cosmetic outcomes 1

Mastectomy Indications

Mastectomy is indicated when:

Tumor size is large relative to breast size 1
Tumor multicentricity is present 1
Negative surgical margins cannot be achieved after multiple resections 1
Prior chest wall radiation or contraindications to radiation therapy exist 1
Patient preference 1

Immediate breast reconstruction should be offered to the vast majority of mastectomy patients, except those with inflammatory cancer. 1, 3

Axillary Management

Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging in clinically node-negative early breast cancer. 1, 2

Further axillary surgery after positive SLNB is NOT required when:

Micrometastases are present 1
One to two sentinel nodes contain metastases AND patient receives postoperative tangential breast radiation 1

Axillary radiation is a valid alternative to axillary dissection in patients with positive SLNB, regardless of breast surgery type. 1

Radiation Therapy

After Breast-Conserving Surgery

Whole breast radiation therapy is mandatory after lumpectomy—it substantially reduces local recurrence and improves survival. 2

Radiation boost to tumor bed:

Standard for patients under 50 years 2
Consider for patients over 50 with risk factors (positive nodes, lymphovascular invasion, close margins) 2

Post-Mastectomy Radiation

Post-mastectomy radiation to chest wall and regional lymph nodes is indicated when:

Four or more positive axillary nodes 3
T3-T4 tumors 3
One to three positive axillary lymph nodes with additional risk factors 3

Systemic Therapy Selection by Subtype

Hormone Receptor-Positive Disease

For premenopausal women with lymph node involvement (N+):

Chemotherapy AND tamoxifen is the standard 1
Tamoxifen as adjuvant treatment in premenopausal women can only be used in association with chemotherapy 1

For postmenopausal women with lymph node involvement (N+):

Tamoxifen is the standard 1
Chemotherapy is an option 1

Duration of tamoxifen therapy:

Five years of tamoxifen is superior to shorter durations 4
Continuation beyond 5 years does not provide additional benefit and may be harmful 4
Tamoxifen reduces contralateral breast cancer incidence by 47% with 5 years of treatment 4

For postmenopausal women, aromatase inhibitors are alternatives to tamoxifen. 3

HER2-Positive Disease

Concurrent taxane and anti-HER2 therapy (trastuzumab) is required for all HER2-positive stage 2 breast cancers, as it increases pathologic complete response rates. 1, 2

Anthracycline-based chemotherapy should be incorporated in the treatment regimen. 1

When anthracycline is given, it must be administered sequentially with anti-HER2 therapy (not concurrently). 1

Triple-Negative Disease

For triple-negative locally advanced breast cancer, anthracycline-and-taxane-based chemotherapy is the standard initial treatment. 1

Chemotherapy is the only systemic treatment option for triple-negative stage 2 breast cancer. 2

Immunotherapy should be considered if PD-L1 positive. 3

Neoadjuvant vs. Adjuvant Therapy

Neoadjuvant systemic therapy should be considered for:

Large stage 2 tumors to enable breast-conserving surgery instead of mastectomy 2
HER2-positive tumors greater than 2 cm 1
Triple-negative tumors greater than 2 cm 1
Positive axilla 1

Treatment sequencing with neoadjuvant approach:

Systemic therapy 2
Surgery 2
Radiation 2
Completion of systemic therapy 2

Treatment sequencing with adjuvant approach:

Surgery 2
Chemotherapy (if indicated) 2
Radiation 2
Endocrine therapy (if hormone receptor-positive) 2

Genetic Counseling and Testing

Every patient with bilateral breast cancer should be offered genetic counseling, preferably before starting treatment. 5

Bilateral breast cancer is an explicit criterion for BRCA1/2 testing regardless of age at diagnosis, even without additional family history. 5

Testing should include:

BRCA1/2 as primary targets 5
Multi-gene panel testing (p53, PALB2, CHEK2, ATM, RAD51C, BRIP1) based on personal and family history 5
CDH1 gene testing for lobular breast cancer 5

BRCA mutation carriers require:

Annual surveillance with MRI and mammography 5
Consideration of risk-reducing bilateral mastectomy 5
Preferential consideration of platinum-based chemotherapy 5

Patient Information and Shared Decision-Making

Information on diagnosis and treatment must be given repeatedly, both verbally and in writing, in a comprehensive and easily understandable form. 1

Patients must be actively involved in all management decisions. 1

The choice of treatment strategy must be extensively discussed with the patient and take into account patient preferences. 1

In younger premenopausal patients, fertility issues and fertility-preservation techniques must be discussed before initiation of any systemic treatment. 1

Age Considerations

Age should be taken into consideration in conjunction with other factors and should NOT be the sole determinant for withholding or recommending treatment. 1

Younger patients should not be overtreated because they are "young," just as older patients should not be undertreated because they are deemed "old." 1

Common Pitfalls to Avoid

Do not omit radiation therapy after breast-conserving surgery—this substantially increases local recurrence risk and reduces survival 2.

Do not perform routine axillary dissection when sentinel lymph node biopsy is negative—this adds morbidity without benefit 2.

Do not accept positive surgical margins—re-excision or mastectomy is required 2.

Do not delay endocrine therapy in hormone receptor-positive disease—it should begin after chemotherapy completion and continue for 5 years (not longer) 2, 4.

Do not use tamoxifen alone in premenopausal women with lymph node-positive disease—it must be combined with chemotherapy 1.

Do not perform genetic testing without adequate pre-test counseling by an appropriately trained professional. 5

Do not delay genetic counseling until after treatment is completed—this misses the opportunity to inform surgical and systemic therapy decisions 5.

What is the recommended treatment approach for a patient with breast cancer or at high risk of developing breast cancer, considering factors such as tumor characteristics, patient age, menopausal status, and genetic predisposition?

Help us tailor your experience